HUP0101139A2 - Transdermal delivery of particulate vaccine compositions - Google Patents

Transdermal delivery of particulate vaccine compositions

Info

Publication number
HUP0101139A2
HUP0101139A2 HU0101139A HUP0101139A HUP0101139A2 HU P0101139 A2 HUP0101139 A2 HU P0101139A2 HU 0101139 A HU0101139 A HU 0101139A HU P0101139 A HUP0101139 A HU P0101139A HU P0101139 A2 HUP0101139 A2 HU P0101139A2
Authority
HU
Hungary
Prior art keywords
transdermal delivery
vaccine compositions
particulate vaccine
needleless syringe
syringe system
Prior art date
Application number
HU0101139A
Other languages
Hungarian (hu)
Inventor
Dexiang Chen
Robert J. Drape
David Sarphie
William F. Swain
Georg J. Widera
Original Assignee
Powderject Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines, Inc. filed Critical Powderject Vaccines, Inc.
Publication of HUP0101139A2 publication Critical patent/HUP0101139A2/en
Publication of HUP0101139A3 publication Critical patent/HUP0101139A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány egy kiválasztott antigén elleni immunválasz fokozásáraalkalmas eljárásra vonatkozik. Az eljárás folyamán porított adjuvánskészítményt adnak be transzdermálisan, előnyösen tű nélküli fecskendő-rendszert használva. Kristályos részecskék gyógyszerkészítményekbőlvaló előállításának módszereit írják le, majd ezeknek betegeknek valóbeadását ismertetik. A kristályosított készítmények különösenalkalmasak transzdermális vakcina beadásra tű nélkülifecskendőrendszert alkalmazva. ÓThe invention relates to a method suitable for enhancing an immune response against a selected antigen. During the procedure, a powdered adjuvant preparation is administered transdermally, preferably using a needleless syringe system. The methods of producing crystalline particles from pharmaceutical preparations are described, and then their administration to patients is described. Crystallized preparations are particularly suitable for transdermal vaccine administration using a needleless syringe system. HE

HU0101139A 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions HUP0101139A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6714697P 1997-12-02 1997-12-02
US8268698P 1998-04-22 1998-04-22
PCT/US1998/025563 WO1999027961A1 (en) 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions

Publications (2)

Publication Number Publication Date
HUP0101139A2 true HUP0101139A2 (en) 2001-07-30
HUP0101139A3 HUP0101139A3 (en) 2003-11-28

Family

ID=26747529

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101139A HUP0101139A3 (en) 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions

Country Status (9)

Country Link
EP (1) EP1035867A1 (en)
JP (1) JP2001524533A (en)
CN (1) CN1285753A (en)
AU (1) AU756828B2 (en)
CA (1) CA2312900A1 (en)
HU (1) HUP0101139A3 (en)
IL (1) IL136488A0 (en)
NZ (1) NZ504894A (en)
WO (1) WO1999027961A1 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
ES2250151T3 (en) * 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. USE OF CPG AS A VACCINE ASSISTANT AGAINST HIV.
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
ATE285806T1 (en) 1999-10-11 2005-01-15 Felton International Inc UNIVERSAL ANTI-INFECTION PROTECTION DEVICE FOR NEEDLELESS INJECTORS
DK1227840T3 (en) * 1999-11-03 2008-02-04 Powderject Vaccines Inc Adjuvanted genetic vaccines
DE69942161D1 (en) * 1999-11-03 2010-04-29 Powderject Vaccines Inc Genetic adjuvant vaccines
WO2001034185A2 (en) * 1999-11-10 2001-05-17 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
JP2003535119A (en) * 2000-06-08 2003-11-25 パウダージェクト ワクチンズ，インコーポレーテッド Powder composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20050019340A1 (en) 2000-10-18 2005-01-27 Nathalie Garcon Vaccines
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
BRPI0515520A (en) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa immunogenic composition, vaccine, methods of preparing a vaccine and preventing or treating staph infection, and use of immunogenic composition
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1951300B1 (en) * 2005-11-04 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Changing th1/th2 balance in split influenza vaccines with adjuvants
EP1951299B1 (en) * 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PL1945252T3 (en) 2005-11-04 2013-11-29 Seqirus Uk Ltd Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3470080A1 (en) 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
PL2054431T3 (en) 2006-06-09 2012-07-31 Novartis Ag Conformers of bacterial adhesins
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
CN101522218B (en) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising an oil in water emulsion adjuvant
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CN101784282B (en) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
CN101969992B (en) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57 mutant antigens and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (en) 2007-12-21 2015-01-21 诺华股份有限公司 Mutant forms of streptolysin o
CA2720961A1 (en) 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
WO2010036938A2 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same
JP2012515157A (en) 2009-01-12 2012-07-05 ノバルティス アーゲー Cna_B domain antigen in vaccine against gram positive bacteria
EA201500910A1 (en) 2009-02-10 2016-04-29 Новартис Аг VACCINES AGAINST FLU WITH REDUCED NUMBER OF SQUALES
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
WO2010148111A1 (en) 2009-06-16 2010-12-23 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5633152B2 (en) * 2010-02-16 2014-12-03 東ソー株式会社 Adjuvant
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP2013529894A (en) 2010-04-07 2013-07-25 ノバルティス アーゲー Method for generating parvovirus B19 virus-like particles
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB2482691B (en) * 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
CN103930436A (en) 2011-09-14 2014-07-16 诺华股份有限公司 Escherichia coli vaccine combination
US9732144B2 (en) 2012-07-05 2017-08-15 Ohio State Innovation Foundation Infectious bursal disease (IBDV) vaccine compositions
CN109134640A (en) 2012-10-23 2019-01-04 爱默蕾大学 GM-CSF and IL-4 conjugates, composition and relative method
CA2888982C (en) 2012-10-24 2020-07-21 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
KR101977449B1 (en) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 Albumin variants and uses thereof
CA2929126C (en) 2013-11-13 2020-01-07 University Of Oslo Outer membrane vesicles and uses thereof
EP3069138B1 (en) 2013-11-15 2019-01-09 Oslo Universitetssykehus HF Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
BR112016012306A2 (en) 2013-12-03 2017-09-26 Swiss Tropical And Public Health Inst proline rich peptides for protection against s. pneumoniae
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST HAND, FEET AND MOUTH DISEASE AND MANUFACTURING AND USE METHODS
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
EP4226936A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2017040387A2 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
CN118063458A (en) 2017-05-22 2024-05-24 托帕杜制药公司 Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
MX2019015524A (en) 2017-06-23 2020-09-10 Univ Maryland Immunogenic compositions.
JP2020533338A (en) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ Vaccine molecule
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
SG11202003796XA (en) 2017-11-03 2020-05-28 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
CN113166157A (en) 2018-11-28 2021-07-23 托帕杜制药公司 Novel double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
US20230233667A1 (en) 2021-09-08 2023-07-27 Affinivax, Inc. Coronavirus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509188A (en) * 1893-11-21 Barton b
US4629782A (en) * 1984-12-21 1986-12-16 Syntex (U.S.A.) Inc. Crystalline form of N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine
CA1337047C (en) * 1988-08-18 1995-09-19 Peter Dodd Cooper Gamma inulin compositions
DK0390435T3 (en) * 1989-03-29 1994-03-21 Takeda Chemical Industries Ltd Mixture containing a compound of the vitamin B group, and preparation thereof
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU5547594A (en) * 1992-11-03 1994-05-24 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
EP0914440B1 (en) * 1996-04-19 2007-01-10 Merial Ltd. Nucleic acid vaccination for parvoviral infections

Also Published As

Publication number Publication date
AU756828B2 (en) 2003-01-23
EP1035867A1 (en) 2000-09-20
WO1999027961A1 (en) 1999-06-10
JP2001524533A (en) 2001-12-04
AU1619999A (en) 1999-06-16
IL136488A0 (en) 2001-06-14
CN1285753A (en) 2001-02-28
CA2312900A1 (en) 1999-06-10
NZ504894A (en) 2002-12-20
HUP0101139A3 (en) 2003-11-28

Similar Documents

Publication Publication Date Title
HUP0101139A2 (en) Transdermal delivery of particulate vaccine compositions
Bienzle et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B‐related disease
US20020160011A1 (en) Adjuvant compositions for vaccines
EE03147B1 (en) Controlled release preparation and methods for its preparation
JP2003507341A5 (en)
Phillips et al. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens
RU94045898A (en) Vaccine composition, method of immune system stimulation
Beignon et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells
ES2565578T3 (en) Cancer vaccines containing oncofetal antigen epitopes
JP2002506001A (en) Mixed lipopeptide micelles for induction of immune response and its therapeutic applications
IL97014A (en) Liposome-containing intranasal vaccine formulation
Perrin et al. Interleukin 2 increases protection against experimental rabies
JP2007513992A (en) Vaccine comprising IL-12 or IL-23 for the treatment of autoimmune diseases
JP2006502228A5 (en)
WO1990011085A1 (en) Large multivalent immunogen
JPH05504756A (en) Compositions with immunostimulatory properties and their applications in human and veterinary medicine
GB9906695D0 (en) Vaccine composition
CA2098726A1 (en) Use of il-4 to enhance immune response to immunogens in vaccines
JP2004508290A (en) Use of granular vectors in immunomodulation
Alexander et al. Adjuvants and their modes of action
JP2001521908A (en) Encapsulated immunomodulators useful as vaccine adjuvants
Pardridge et al. Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine
Cerutti et al. Importance of coordinated immune stimulation in experimental antitumor treatment
JP2002291498A (en) METHOD FOR ASSAYING ABILITY TO INDUCE IFN-gamma PRODUCTION
JP2001292794A (en) METHOD FOR ASSAYING IFN-gamma PRODUCTION INDUCING ABILITY

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees